vancomycin against e faecalis atcc 29212 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
vancomycin against e faecalis atcc 29212
Vancomycin Against E Faecalis Atcc 29212, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 9952 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vancomycin+against+e+faecalis+atcc+29212/Enterococcus+faecalis/pm41691191-233-10-14
Average 99 stars, based on 9952 article reviews
Vancomycin Against E Faecalis Atcc 29212, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 9952 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vancomycin+against+e+faecalis+atcc+29212/Enterococcus+faecalis/pm41691191-233-10-14
Average 99 stars, based on 9952 article reviews
vancomycin against e faecalis atcc 29212 - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Inhibition:Article Title: Evaluation of the antibacterial activity of three gutta-percha solvents against Enterococcus faecalis. Article Snippet: Purpose: Enterococcus faecalis (E. faecalis) is implicated as the common etiological agent of root canal treatment failure.. The study was aimed to compare the antibacterial efficacy and to assess the minimum inhibitory concentration (MIC) of 3 gutta-percha solvents RC Solve, Endosolv-E, and xylene against E. faecalis.. Methods: Agar well diffusion assay was performed to evaluate the antibacterial efficacy of the guttapercha solvents against E. faecalis (ATCC 29212 and a clinical isolate). Bacteria:Article Title: Cloxiquine exerts bactericidal activity against Enterococcus faecalis through disruption of proton motive force and induction of reactive oxygen species. Article Snippet: PAE and PA-SME of Cloxiquine. (A) PAE of Cloxiquine and vancomycin against E. faecalis ATCC 29212 and EFA 5. .. Bacteria were exposed to the antibiotics at 1-4×MIC, followed by drug removal and subsequent viable cell count at the indicated time points. (B) PA-SME of Cloxiquine and Cell Characterization:Article Title: Cloxiquine exerts bactericidal activity against Enterococcus faecalis through disruption of proton motive force and induction of reactive oxygen species. Article Snippet: PAE and PA-SME of Cloxiquine. (A) PAE of Cloxiquine and vancomycin against E. faecalis ATCC 29212 and EFA 5. .. Bacteria were exposed to the antibiotics at 1-4×MIC, followed by drug removal and subsequent viable cell count at the indicated time points. (B) PA-SME of Cloxiquine and Activity Assay:Article Title: BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection. Article Snippet: An experimental study was performed to evaluate the efficacy of BMAP-28 alone and in combination with vancomycin in animal models ureteral stent infection due to Enterococcus faecalis and Staphylococcus aureus.. Study included a control group without bacterial challenge to evaluate the sterility of surgical procedure, a challenged control group that did not receive any antibiotic prophylaxis and for each bacterial strain three challenged groups that received (a) 10 mg/kg vancomycin intraperitoneally, immediately after stent implantation, (b) BMAP-28-coated ureteral stents where 0.2-cm sterile ureteral stents were incubated in 1 mg/l BMAP-28 solution for 30 min immediately before implantation and (c) intraperitoneal vancomycin plus BMAP-28-coated ureteral stent at the above concentrations.. Experiments were performed in duplicate. Infection:Article Title: BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection. Article Snippet: An experimental study was performed to evaluate the efficacy of BMAP-28 alone and in combination with vancomycin in animal models ureteral stent infection due to Enterococcus faecalis and Staphylococcus aureus.. Study included a control group without bacterial challenge to evaluate the sterility of surgical procedure, a challenged control group that did not receive any antibiotic prophylaxis and for each bacterial strain three challenged groups that received (a) 10 mg/kg vancomycin intraperitoneally, immediately after stent implantation, (b) BMAP-28-coated ureteral stents where 0.2-cm sterile ureteral stents were incubated in 1 mg/l BMAP-28 solution for 30 min immediately before implantation and (c) intraperitoneal vancomycin plus BMAP-28-coated ureteral stent at the above concentrations.. Experiments were performed in duplicate. Control:Article Title: BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection. Article Snippet: An experimental study was performed to evaluate the efficacy of BMAP-28 alone and in combination with vancomycin in animal models ureteral stent infection due to Enterococcus faecalis and Staphylococcus aureus.. Study included a control group without bacterial challenge to evaluate the sterility of surgical procedure, a challenged control group that did not receive any antibiotic prophylaxis and for each bacterial strain three challenged groups that received (a) 10 mg/kg vancomycin intraperitoneally, immediately after stent implantation, (b) BMAP-28-coated ureteral stents where 0.2-cm sterile ureteral stents were incubated in 1 mg/l BMAP-28 solution for 30 min immediately before implantation and (c) intraperitoneal vancomycin plus BMAP-28-coated ureteral stent at the above concentrations.. Experiments were performed in duplicate. |